Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Ozurdex (dexamethasone) in the treatment of patients with retinal vein occlusion (RVO)
- Orladeyo (berotralstat) in the preventive treatment of patients with recurrent attacks of severe hereditary angioedema
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
